This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to a study released in The Lancet Global Health on Wednesday, Oct. 27, 2021, Fluvoxamine, a cheap antidepressant, reduced the need for hospitalization among high-risk adults with COVID-19. (NIAID-RML via AP)
By Carla K. Johnson
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.
They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”
The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.
Researchers tested the antidepressant in nearly 1,500 Brazilians recently infected with coronavirus who were at risk of severe illness because of other health problems, such as diabetes. About half took the antidepressant at home for 10 days, the rest got dummy pills. They were tracked for four weeks to see who landed in the hospital or spent extended time in an emergency room when hospitals were full.
In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.
The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.
Questions remain about the best dosing, whether lower risk patients might also benefit and whether the pill should be combined with other treatments.
The larger project looked at eight existing drugs to see if they could work against the pandemic virus. The project is still testing a hepatitis drug, but all the others — including metformin, hydroxychloroquine and ivermectin — haven't panned out.
The cheap generic and Merck's COVID-19 pill work in different ways and “may be complementary,” said Dr. Paul Sax of Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the study. Earlier this month, Merck asked regulators in the U.S. and Europe to authorize its antiviral pill.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
A deal was reached as the COP26 Summit in Glasgow came to a close. Dr. Katharine Hayhoe, Chief Scientist at the Nature Conservancy and Author of 'Saving Us: A Climate Scientist's Case for Hope and Healing in a Divided World,' joined Cheddar News' Closing Bell to discuss the deal.
Over the years many people have gotten into the act of living a sustainable life all in the hopes of helping to protect and save the plant. However, some argue that living in this kind of fashion is expensive and only accessible to the wealthy. Editor at Large at CNET Farnoosh Torabi, joined Cheddar to discuss more.
As we move into the colder months in the U.S., health experts are warning of a more active flu season than last year, sounding the alarm on what many are calling a 'twindemic.' Dr. Syra Madad, infectious disease epidemiologist, joined Cheddar's 'Search for the Cure' to discuss the intersection of the flu season with the Covid-19 pandemic.
The UN climate summit wrapped up over the weekend after days of negotiations over the summit's final agreement. The agreement pushes countries to reassess their climate goals by the end of next year, do more for countries facing the worst effects of climate change, and also calls for a "phase down" of coal and other fossil fuel subsidies. The White House praised the agreement, but underscored the feelings of many world leaders by saying it isn't enough.
Deborah Brosnan, climate expert and president of Deborah Brosnan and Associates, joined Cheddar's News Wrap to discuss.
Dr. Joseph Sellers, President of the Medical Society of the State of New York and Pediatrician at Basset Medical Group, joined Cheddar News for an update on vaccinations for kids under 12 now that the rollout has officially begun.
President Biden is under some pressure from members of his own party over rising gas prices. Senate Majority Leader Chuck Schumer has called for the president to utilize oil reserves to lower gas prices ahead of the holiday season, as gas prices are currently at a seven-year high. Energy Workforce & Technology Council CEO Leslie Beyer joins Cheddar News' Closing Bell to discuss.
Russia is being blamed for putting the International Space Station and its crew at risk after it fired a missile during a weapons test at a non-functional satellite. NASA has said that the debris from the explosion could potentially orbit the Earth for decades.
Cases of covid-19 are climbing in the Upper Midwest, Southwest, and parts of the Northeast. The seven-day national average is sitting at roughly 82,000 new cases which is an 11 percent jump from the week before. Dr. Amesh Adalja, Infectious Disease, Specialist, Sr. Scholar at Johns Hopkins Center for Health Security joined Cheddar's Opening Bell to discuss this recent uptick ahead of the holiday season.
Jill is joined by Baker Machado to talk all things infrastructure: where will the money go and who’s in charge? Plus, Sesame Street has its first Asian-American muppet. And a trailer for the trailer for Spiderman. Huh?
Booking.com has unveiled a first-of-its-kind sustainable travel designation for properties that might be on the itinerary of a climate-conscious traveler. CEO Glenn Fogel explained to Cheddar the key metrics a location has to achieve to earn a sustainability badge. Waste handling, energy and greenhouse gases, water usage, local community support, and protection of nature were the five top areas of concern he addressed, with an additional subset of 32 measures that properties can implement.
